HealthQuill Articles by: HealthQuill
Merck & Co.’s two oral cholesterol pill trials — one mid-stage and the other end-stage — showed “positive top-line results” on the efficacy and safety of the treatment in adults, according to the company.
Drugs Health Pharma

Merck’s oral pill for bad cholesterol shows ‘positive’ data during trials

HQ Team June 10, 2025: Merck & Co.’s two oral cholesterol pill trials — one mid-stage and the other end-stage — showed “positive

Read More
Underreporting of brain tumour cases and non-availability of neuroimaging facilities in India may be the cause of the low prevalence of the disease in the South Asian nation, experts say.
Drugs Health Pharma

India’s few neuroimaging units hinder tracking brain tumours

HQ Team June 10, 2025:Underreporting of brain tumour cases and non-availability of neuroimaging facilities in India may be the cause of the low

Read More
The Food and Drug Administration has approved Merck & Co. Inc.’s jab for preventing respiratory syncytial virus (RSV) in infants up to one year of age for the first RSV season.
Drugs Health Pharma

Merck & Co.’s RSV injection for infants gets nod from US drug regulator

HQ Team June 10, 2025: The Food and Drug Administration has approved Merck & Co. Inc.’s jab for preventing respiratory syncytial virus (RSV)

Read More
Mpox cases continue to surge and meet the criteria of a public health emergency of international concern, the World Health Organization stated.
Health Medical Pharma

WHO maintains mpox as a public health emergency of global concern

HQ Team June 10, 2025: Mpox cases continue to surge and meet the criteria of a public health emergency of international concern, the

Read More
Canadian researchers have discovered a new candidate to fight drug-resistant bacteria, about three decades after the last antibiotic was developed to fight antimicrobial resistance (AMR).
Health Medical Research

Canadian researchers discover first molecule in 30 years to fight AMR

HQ Team June 9, 2025: Canadian researchers have discovered a new candidate to fight drug-resistant bacteria, about three decades after the last antibiotic

Read More
A virus belonging to the bat family, and closely related to the deadly Middle East respiratory syndrome coronavirus (MERS-CoV), may be a small mutation away from spilling over to humans and causing a pandemic.
Climate Health Research

Bat family virus, similar to MERS-CoV, has potential to cause a pandemic

 HQ Team June 9, 2025: A virus belonging to the bat family, and closely related to the deadly Middle East respiratory syndrome coronavirus

Read More
Mental disorders have risen 70% across three decades, starting in 1990, in the Association of Southeast Asian Nations (ASEAN), affecting 80 million people in the region, according to a study.
Drugs Health Research

Mental disorders in ASEAN rise 70% in three decades: IHME, NUS study

HQ Team June 5, 2025: Mental disorders have risen 70% across three decades, starting in 1990, in the Association of Southeast Asian Nations

Read More
Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales threshold of its antifungal therapy in the Asia Pacific region, triggering a milestone payment.
Drugs Health Pharma

Sales surge triggers Pfizer’s $2.5 million milestone payment to Basilea

HQ Team June 5, 2025: Pfizer Inc. will pay Basilea Pharmaceutica Ltd. $ 2.5 million as the Swiss biopharmaceutical company exceeded the sales

Read More
Paradromics Inc., a US-based neurotechnology company, has completed its first-in-human surgical placement of its brain-computer interface.
Drugs Health Medical

Paradromics places brain-computer device in human, rivals Neuralink

HQ Team June 5, 2025: Paradromics Inc., a US-based neurotechnology company, has completed its first-in-human surgical placement of its brain-computer interface. The safe

Read More
Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products for diabetes and other chronic diseases.
Drugs Health Pharma

Lilly, Sweden’s Camurus sign $870 million pact for incretin products

HQ Team June 4, 2025: Eli Lilly and Company and Sweden’s Camurus AB have signed a $870 million pact to develop incretin products

Read More